Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating Activities:
Net loss	$ (59,312)	$ (154,201)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Goodwill and intangible assets impairment	0	86,881
Depreciation	2,898	2,166
Amortization of intangible assets	10,801	10,301
Amortization of debt discount and debt issuance costs	0	1,513
Amortization of short-term investment discount	0	(327)
Stock-based compensation	7,911	11,508
Interest expense on deferred consideration - MST acquisition	0	756
Deferred tax benefit	(1,516)	(3,224)
Bad debt expense	0	1,634
Write down of inventory	0	8,931
Change in fair value of warrant liabilities	336	(2,248)
Change in fair value of contingent consideration	2,924	(9,553)
Loss on extinguishment of debt	0	1,006
Changes in operating assets and liabilities:
Accounts receivable	(447)	6,083
Interest receivable	0	26
Inventories	(7,198)	(16,404)
Other current and long term assets	2,296	(655)
Accounts payable	(1,758)	(668)
Accrued expenses	(2,645)	(1,180)
Deferred revenue	(105)	(959)
Other long term liabilities	(860)	998
Net cash and cash equivalents used in operating activities	(46,675)	(73,484)
Investing Activities:
Proceeds from sale of AutoLap assets	0	15,965
Purchase of short-term investments	0	(12,883)
Proceeds from maturities of short-term investments	0	65,000
Purchase of property and equipment	(3)	(437)
Net cash and cash equivalents (used in) provided by investing activities	(3)	67,645
Financing Activities:
Proceeds from issuance of common stock, preferred stock and warrants under 2020 financing, net of issuance costs	13,478	0
Proceeds from issuance of common stock, net of issuance costs	33,847	25,777
Proceeds from notes payable, net of issuance costs	2,815	0
Payment of note payable	0	(31,425)
Taxes paid related to net share settlement of vesting of restricted stock units	(36)	(499)
Payment of contingent consideration	(74)	0
Proceeds from exercise of stock options and warrants	3,340	538
Net cash and cash equivalents provided by (used in) financing activities	53,370	(5,609)
Effect of exchange rate changes on cash and cash equivalents	270	364
Net increase in cash, cash equivalents and restricted cash	6,962	(11,084)
Cash, cash equivalents and restricted cash, beginning of period	10,567	21,651
Cash, cash equivalents and restricted cash, end of period	17,529	10,567
Supplemental Disclosure for Cash Flow Information:
Interest paid	0	2,187
Supplemental Schedule of Non-cash Investing and Financing Activities:
Transfer of inventories to property and equipment	8,113	486
Exchange of common stock for Series B Warrants	2,470	0
Transfer of in-process research and development to intellectual property	2,425	0
Deemed dividend related to beneficial conversion feature of preferred stock	412	0
Deemed dividend related to conversion of preferred stock into common stock	299	0
Issuance of common stock - MST acquisition	0	6,600
Proceeds from sale of AutoLap assets exchanged for settlement of Company obligations	0	1,000
Transfer of property and equipment to inventories	0	323
Conversion of preferred stock to common stock	79	0
Auto Lap [Member]
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Gain (loss) from sale of assets	0	(15,965)
SurgiBot System [Member]
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Gain (loss) from sale of assets	$ 0	$ 97